Search clinical trials for: ISIS CRP Rx or Placebo

Total 1129 results

Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Rheumatoid Arthritis

Canada, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation (ASET)

Paroxysmal Atrial Fibrillation

United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Elevated Lipoprotein(a)

Netherlands, United Kingdom, Denmark, Germany, Canada
Ionis Pharmaceuticals, Inc.
Bayer

Completed

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

End-stage Renal Disease (ESRD)

Canada
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

New Zealand, United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Biogen

Completed

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) (SMNRx)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

United States, Canada
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)

Spinal Muscular Atrophy

United States
University of Chicago
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

CommunityRx-Hunger (CRx-H)

Food Insecurity

United States
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
University of Chicago
National Institute on Aging (NIA)

Enrolling by invitation

CommunityRx-Dementia (CRx-D)

Health Related Social Needs (HRSN)

United States
Ionis Pharmaceuticals, Inc.

Completed

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients (FGFR4-CS2)

Obesity

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
National Institute of Diabetes and Digestive and...

Completed

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

Lipodystrophy

United States
Ionis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Type 2 Diabetes

Austria
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada, France, Germany, United Kingdom, Netherlands
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, South Africa
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Mild Alzheimer's Disease

United Kingdom, Netherlands, Germany, Sweden, Canada, Finland
University of Virginia

Active, not recruiting

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)

Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAF

United States
Ionis Pharmaceuticals, Inc.

Completed

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

United States
Smith, Timothy R., M.D.
Ionis Pharmaceuticals, Inc.; Clinvest Research, LLC

Completed

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

Chronic Migraine

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Elevated Triglycerides (TG)

Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Type 2 Diabetes Mellitus | Obese

Argentina, Canada, South Africa
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Terminated

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Familial Partial Lipodystrophy

United States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
Medtronic Bakken Research Center
Medtronic; FRANCE

Completed

Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial (V3)

Heart Failure

France
Rexahn Pharmaceuticals, Inc.

Completed

Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)

Erectile Dysfunction (ED)

United States
Medtronic Bakken Research Center
Medtronic

Terminated

X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure

Heart Failure, Congestive

Germany
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC)

Non-small Cell Lung Cancer

United States, Hungary, Poland, Russian Federation
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

Healthy Volunteers

Canada
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Not yet recruiting

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT (RIGHT-CRT)

Congenital Heart Disease | Transposition of Great Vessels | Congenitally Corrected Transposition of the Great Arteries | Systemic Right Ventricle | Heart Failure Congenital

France
Biotronik France
Biotronik SE & Co. KG

Completed

Observational Study of Patient Comprehension, Perception, Fears and Appreciation Following Home-Monitoring Implementation (Educ@t)

Tachycardia | Defibrillators

France
Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

United States, Belgium, Spain, Poland, Taiwan, France, Bulgaria, Netherlands, Brazil, Italy, Czechia, Canada, Greece, Portugal, Argentina, Malaysia, Mexico, Slovakia, Sweden, Hungary, India, Romania, Lithuania
Ionis Pharmaceuticals, Inc.

Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Hypertriglyceridemia | Atherosclerotic Cardiovascular Disease | Severe Hypertriglyceridemia

United States, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE)

Familial Chylomicronemia Syndrome

United States, Israel, Spain, Italy, United Kingdom, Netherlands, Canada, Hungary, Sweden, France, Norway, Portugal, Slovakia
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Hypercholesterolemia

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Hypercholesterolemia

Netherlands, United States
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

Finland, United States, France, Israel, Netherlands, Denmark, Spain, Australia, United Kingdom, Germany, Italy, Canada, Czechia, Turkey, Hungary, Bulgaria, New Zealand, Sweden, South Africa, Poland, Norway, Portugal, Slovakia
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Cardiovascular Diseases | Atherosclerosis | Hypertriglyceridemia

United States, Spain, Italy, Denmark, Hungary, Netherlands, Canada, France, Poland, Bulgaria, Czechia, Portugal, Slovakia, Norway
University Hospital, Lille
Biotronik France

Completed

Efficacy, Safety and Cost of Remote Monitoring of Patients With Cardiac Resynchronization Therapy (ECOST-CRT)

Heart Failure | Cardiac Resynchronization Therapy

France
Microbicide Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Completed

Assessment of ASPIRE and HOPE Adherence

HIV Prevention

Zimbabwe, Malawi, South Africa, Uganda
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Columbia University

Terminated

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Breast Cancer | Colon Cancer | Neuropathy

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Type 2 Diabetes Mellitus

Canada, Romania, South Africa

Search clinical trials for: ISIS CRP Rx or Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations